
66 pts screened
8/04-9/09
43 screen failures
36 HLA-A2 negative
4 withdrew consent
1 with incorrect pathology
1 did not express CEA
1 with elevated bilirubin
23 patients randomized
4 patients never treated
3 patients with a declining PS
1 patient with a GI bleed
19 patients received at least one dose of CEA-vac and eligible for secondary endpoint
Arm A: 5
0.01 mg
Arm B: 8
0.1 mg
Arm C: 6
1 mg
14 patients received at least 3 doses of CEA-vac and eligible for primary immunologic endpoint
Arm A: 5
Arm B: 5
Arm C: 4